Regulacje i polityka gospodarcza · 23/09/2016

Cogentis Therapeutics to Receive Exclusive License for Therapies for Frontotemporal Dementia and Neurological Disorders

The National Institute of Neurological Disorders and Stroke is considering granting Cogentis Therapeutics an exclusive license to develop and commercialize therapies for frontotemporal dementia, Alzheimer's disease, and other neurological conditions, with the potential for global distribution.